Enzymatic Assay Determines Creatinine in Serum, Plasma, and Urine

An enzymatic method for the quantitative determination of creatinine in human serum, plasma, and urine complements current methods by increasing accuracy and reducing interference issues for specific patients. Creatinine measurement is the most commonly used indicator of renal function and is used for monitoring patients with renal failure and those undergoing renal dialysis.

Olympus (Hamburg, Germany) introduced the new enzymatic creatinine assay, which is suitable for use across the range of the company's diagnostic analyzers. The new assay complements the current Jaffe method, providing increased accuracy of creatinine measurements for patients suffering from diabetes, renal failure, liver failure, and hepatitis.

The new assay employs the same calibrators and controls as the current Jaffe method; however, to ensure optimal traceability, new set points for calibrator and target values, as well as ranges for control sera have been assigned. Sold in a kit format, the reagent has improved on board stability of 60 days, a calibration stability of 14 days for serum, and 30 days for urine.

Extremely precise and accurate, the enzymatic assay demonstrates excellent agreement with the gas chromatography/mass spectrometry (GC/MS) reference method. The limit of detection for creatinine using serum settings on an Olympus AU640 analyzer was established at 0.88 µmol/l. The assay meets the [U.S.] national kidney disease education program (NKDEP) guidelines and minimizes errors in calculated glomerular filtration rate (cGFR) calculations

Related Links:
Olympus